Fibrinogen exacerbates GCase ubiquitination via ATF5-induced TRIP12 activation in Parkinson's Disease

Background: Blood-brain-barrier disruption occurs in Parkinson's disease (PD), which may be accompanied with the deposition of Fibrinogen (FG) in brain parenchyma. However, the relationship between FG and glucocerebrosidase (GCase) reduction, which may contribute to α-synuclein aggregation in PD, is under investigation. Recently, there is evidence that PD patients without GBA mutation also exhibits GCase reduction in brain, and Thyroid-Hormone-Receptor-Interactor-12 (TRIP12) was found to be a key ubiquitin enzyme of GCase degradation.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research